Pulse Biosciences Reports Q3 2026 Revenue Growth Driven by Vybrance Commercial Volume
Pulse Biosciences (PLSE) reported third-quarter 2026 revenue of $395,000, a significant increase from $86,000 in the prior year period. This growth was primarily driven by increased commercial case volumes within its Vybrance customer base. Despite the revenue rise, the company reported a non-GAAP net loss of $17.5 million, attributed to higher personnel costs and intensified investments in clinical trials. The company strengthened its balance sheet through equity financing, ending the quarter with $189.2 million in cash and marketable securities. Clinical progress remains a central focus, with the Nano-Pulse AF study completing enrollment three months ahead of schedule. Management provided updated timelines for regulatory milestones, including CE Mark approval targets for Q4 2027 and a PMA submission scheduled for the second half of 2027.
Tickers: $PLSE
Topics: clinical trials equity financing regulatory timeline revenue growth